Zhang Q, Li L, Qian X
Hum Vaccin Immunother. 2025; 21(1):2471058.
PMID: 39996388
PMC: 11864310.
DOI: 10.1080/21645515.2025.2471058.
Zhao M, Zhou L, Zhang Q, Wang M, Dong Y, Wang Y
Adv Sci (Weinh). 2025; 12(10):e2407900.
PMID: 39840525
PMC: 11904982.
DOI: 10.1002/advs.202407900.
Zhao L, Gui Y, Cai J, Deng X
Mol Cancer. 2025; 24(1):17.
PMID: 39815289
PMC: 11734411.
DOI: 10.1186/s12943-025-02225-w.
Li Y, Cheng Z, Li S, Zhang J
Heliyon. 2025; 11(1):e41354.
PMID: 39811287
PMC: 11731577.
DOI: 10.1016/j.heliyon.2024.e41354.
Masui H, Kawada K, Obama K
Int J Mol Sci. 2025; 26(1.
PMID: 39795864
PMC: 11720084.
DOI: 10.3390/ijms26010006.
Advancements in immunotherapy for colorectal cancer treatment: a comprehensive review of strategies, challenges, and future prospective.
Kaviyarasan V, Das A, Deka D, Saha B, Banerjee A, Sharma N
Int J Colorectal Dis. 2024; 40(1):1.
PMID: 39731596
PMC: 11682016.
DOI: 10.1007/s00384-024-04790-w.
From Subtypes to Solutions: Integrating CMS Classification with Precision Therapeutics in Colorectal Cancer.
Ding X, Huang H, Fang Z, Jiang J
Curr Treat Options Oncol. 2024; 25(12):1580-1593.
PMID: 39589648
DOI: 10.1007/s11864-024-01282-5.
Insights into the historical trajectory and research trends of immune checkpoint blockade in colorectal cancer: visualization and bibliometric analysis.
Chang Y, Zhou X, Nie K, Liu J, Zhang S
Front Immunol. 2024; 15:1478773.
PMID: 39544944
PMC: 11560439.
DOI: 10.3389/fimmu.2024.1478773.
Targeting PLCG2 Suppresses Tumor Progression, Orchestrates the Tumor Immune Microenvironment and Potentiates Immune Checkpoint Blockade Therapy for Colorectal Cancer.
Zhou X, Lin J, Shao Y, Zheng H, Yang Y, Li S
Int J Biol Sci. 2024; 20(14):5548-5575.
PMID: 39494327
PMC: 11528457.
DOI: 10.7150/ijbs.98200.
CCT6A functions as promising diagnostic biomarker and promotes cell proliferation in colorectal cancer.
Ma J, Wei Q, Zhang L, Sun F, Li W, Du R
J Cancer. 2024; 15(18):5897-5909.
PMID: 39440061
PMC: 11493007.
DOI: 10.7150/jca.98901.
SET facilitates immune escape of microsatellite stability colorectal cancer by inhibiting c-Myc degradation.
Gao L, Li Y, Wang H, Liu J, Zhang R, Shan W
Cancer Sci. 2024; 116(1):29-43.
PMID: 39420583
PMC: 11711062.
DOI: 10.1111/cas.16368.
Evaluation of the efficacy and safety of first- and second-line immunotherapy in patients with metastatic colorectal cancer: a systematic review and network meta-analysis based on randomized controlled trials.
Chen K, Chen W, Yue R, Zhu D, Cui S, Zhang X
Front Immunol. 2024; 15:1439624.
PMID: 39359729
PMC: 11444977.
DOI: 10.3389/fimmu.2024.1439624.
Improving the efficacy of immunotherapy for colorectal cancer: Targeting tumor microenvironment-associated immunosuppressive cells.
Zou D, Xin X, Xu Y, Xu H, Huang L, Xu T
Heliyon. 2024; 10(16):e36446.
PMID: 39262952
PMC: 11388603.
DOI: 10.1016/j.heliyon.2024.e36446.
Impact and potential value of immunosenescence on solid gastrointestinal tumors.
Zhang T, Wen R, Fan H, Yu Y, Jia H, Peng Z
Front Immunol. 2024; 15:1375730.
PMID: 39007138
PMC: 11239362.
DOI: 10.3389/fimmu.2024.1375730.
A hot and cold tumor‑related prognostic signature for stage II colorectal cancer.
Zhou M, Ge X, Xu X, Sheng B, Wang H, Shi H
Oncol Lett. 2024; 28(3):419.
PMID: 39006949
PMC: 11240279.
DOI: 10.3892/ol.2024.14552.
Senescence-related signatures predict prognosis and response to immunotherapy in colon cancer.
Hu X, Zhu X, Chen Y, Zhang W, Li L, Liang H
J Gastrointest Oncol. 2024; 15(3):1020-1034.
PMID: 38989417
PMC: 11231866.
DOI: 10.21037/jgo-24-339.
Region-Specific CD16 Neutrophils Promote Colorectal Cancer Progression by Inhibiting Natural Killer Cells.
Zhang Y, Wang Z, Lu Y, Sanchez D, Li J, Wang L
Adv Sci (Weinh). 2024; 11(29):e2403414.
PMID: 38790136
PMC: 11304263.
DOI: 10.1002/advs.202403414.
Identification of the molecular subtypes and signatures to predict the prognosis, biological functions, and therapeutic response based on the anoikis-related genes in colorectal cancer.
Zhai X, Chen B, Hu H, Deng Y, Chen Y, Hong Y
Cancer Med. 2024; 13(10):e7315.
PMID: 38785271
PMC: 11117457.
DOI: 10.1002/cam4.7315.
Mechanisms of myeloid-derived suppressor cell-mediated immunosuppression in colorectal cancer and related therapies.
Nie S, Jing Y, Lu L, Ren S, Ji G, Xu H
World J Gastrointest Oncol. 2024; 16(5):1690-1704.
PMID: 38764816
PMC: 11099432.
DOI: 10.4251/wjgo.v16.i5.1690.
Exploration of the Molecular Mechanism of Salisb's Anticolorectal Cancer Activity via the Integrative Approach of Network Pharmacology and Experimental Validation.
Yin Z, Tan W, Jiang Y
ACS Omega. 2024; 9(19):21426-21439.
PMID: 38764617
PMC: 11097187.
DOI: 10.1021/acsomega.4c01759.
